NASDAQ:RDHL Redhill Biopharma (RDHL) Stock Price, News & Analysis $0.42 -0.01 (-2.78%) As of 10:09 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsInsider TradesNews and TrendsOwnershipSEC Filings About Redhill Biopharma Stock (NASDAQ:RDHL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Redhill Biopharma alerts:Sign Up Key Stats Today's Range$0.39▼$0.4350-Day Range$0.39▼$0.9052-Week Range$0.38▼$1.60Volume2,692 shsAverage Volume820,365 shsMarket Capitalization$3.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and infectious diseases. The company was founded in Israel and later operated as a publicly traded company in the United States under the ticker symbol RDHL. RedHill’s principal commercial product was Talicia, an oral combination of omeprazole, amoxicillin and rifabutin approved by the U.S. Food and Drug Administration for the treatment of Helicobacter pylori infection in adults. The company also pursued investigational therapies for gastrointestinal disorders, including Crohn’s disease and other inflammatory or infectious conditions, as well as treatments for certain viral infections. RedHill subsequently wound down its operations and was delisted from Nasdaq. Accordingly, historical descriptions of the company and its products may not reflect an active operating business or current commercial availability.AI Generated. May Contain Errors. Read More Redhill Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreRDHL MarketRank™: 0.579997267385 of 5 starsRedhill Biopharma scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingRedhill Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageRedhill Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Redhill Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioRedhill Biopharma has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.55% of the float of Redhill Biopharma has been sold short.Short Interest Ratio / Days to CoverRedhill Biopharma has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Redhill Biopharma has recently decreased by 39.24%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRedhill Biopharma does not currently pay a dividend.Dividend GrowthRedhill Biopharma does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Redhill Biopharma this week, compared to 1 article on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Redhill Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders6.81% of the stock of Redhill Biopharma is held by insiders.Percentage Held by Institutions7.20% of the stock of Redhill Biopharma is held by institutions.Read more about Redhill Biopharma's insider trading history. Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Redhill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RDHL Stock News HeadlinesRedHill Biopharma’s RHB-204 shows MAP-killing efficacy in Crohn’s DiseaseNovember 2, 2026 | tipranks.comTwo Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease CandidateNovember 2, 2026 | prnewswire.comTesla pays zero dividends but this new fund pays monthlyTesla has never paid shareholders a dividend, not one cent. A new fund built on Tesla's stock takes a different approach, paying $452 in monthly cash on a $5,000 stake. Elon Musk recently floated a Tesla-SpaceX merger, but the dividend gap remains unchanged. Similar funds now exist for Apple, Amazon, Microsoft and Nvidia, each designed to turn big tech exposure into monthly income.November 9 at 1:00 AM | Investors Alley (Ad)$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple MyelomaOctober 19, 2026 | prnewswire.comRedHill Biopharma Announces Operational Highlights and First Half 2026 Financial ResultsSeptember 30, 2026 | prnewswire.comRedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?September 10, 2026 | finance.yahoo.comRedhill Biopharma stock doubles in one session — here's whySeptember 1, 2026 | msn.comRedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®September 1, 2026 | markets.businessinsider.comSee More Headlines RDHL Stock Analysis - Frequently Asked Questions How have RDHL shares performed this year? Redhill Biopharma's stock was trading at $1.03 at the beginning of the year. Since then, RDHL stock has decreased by 59.6% and is now trading at $0.4160. How were Redhill Biopharma's earnings last quarter? Redhill Biopharma Ltd. (NASDAQ:RDHL) issued its earnings results on Tuesday, November, 30th. The biotechnology company reported ($500.00) EPS for the quarter, missing analysts' consensus estimates of ($480.00) by $20.00. The biotechnology company earned $21.61 million during the quarter, compared to analysts' expectations of $23.41 million. When did Redhill Biopharma's stock split? Redhill Biopharma's stock reverse split on Tuesday, August 20th 2024.The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Redhill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Redhill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Redhill Biopharma investors own include NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Alibaba Group (BABA), Sorrento Therapeutics (SRNE), Micron Technology (MU) and Tesla (TSLA). Company Calendar Today11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, RDHL's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RDHL Previous SymbolASX:RDH CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees210Year Founded2009Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick RatioN/A Sales & Book Value Annual Sales$290 thousand Price / Sales13.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book0.52Miscellaneous Outstanding Shares8,890,000Free Float8,283,000Market Cap$3.80 million OptionableNo Data Beta4.93 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:RDHL) was last updated on 11/9/2026 by MarketBeat.com Staff. From Our PartnersTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredOne bank just ran the numbers on gold for the next 5 yearsDeutsche Bank's research team just modeled where gold could land by 2031 if central banks keep shifting reserv...Cedar Gold Group | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDHL Stock Alerts